Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
The latest announcement is out from AbCellera Biologics ( (ABCL) ).
On May 12, 2025, AbCellera Biologics announced that the United States Court of Appeals for the Federal Circuit affirmed the validity of its U.S. Patent No. 10,087,408, which pertains to microfluidic devices used for culturing and selectively recovering cells. This decision follows a challenge by Bruker Cellular Analysis, Inc., which was rejected by the U.S. Patent Trial and Appeal Board and now confirmed by the Federal Circuit. This ruling strengthens AbCellera’s intellectual property portfolio and supports its ongoing patent infringement litigation against Bruker in the U.S. District Court for the Northern District of California.
The most recent analyst rating on (ABCL) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.
Spark’s Take on ABCL Stock
According to Spark, TipRanks’ AI Analyst, ABCL is a Neutral.
AbCellera Biologics exhibits a challenging financial and technical landscape, with declining revenues, profitability issues, and weak technical indicators. Although strategic drug development provides some future potential, current valuation metrics and financial performance are concerning, resulting in a low overall stock score.
To see Spark’s full report on ABCL stock, click here.
More about AbCellera Biologics
AbCellera Biologics Inc. is a biotechnology company that discovers and develops antibody medicines for various therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. The company utilizes a platform that integrates technology, data science, infrastructure, and interdisciplinary teams to address complex antibody discovery challenges. AbCellera focuses on advancing an internal pipeline of first-in-class and best-in-class programs and collaborates on innovative drug development programs with partners.
Average Trading Volume: 4,308,155
Technical Sentiment Signal: Sell
Current Market Cap: $614.9M
See more data about ABCL stock on TipRanks’ Stock Analysis page.